These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 11488626)

  • 1. A microtiter plate assay for polyglutamine aggregate extension.
    Berthelier V; Hamilton JB; Chen S; Wetzel R
    Anal Biochem; 2001 Aug; 295(2):227-36. PubMed ID: 11488626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of polyglutamine aggregate cytotoxicity by a structure-based elongation inhibitor.
    Thakur AK; Yang W; Wetzel R
    FASEB J; 2004 May; 18(7):923-5. PubMed ID: 15001566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-like features of polyglutamine aggregates and their assembly kinetics.
    Chen S; Berthelier V; Hamilton JB; O'Nuallain B; Wetzel R
    Biochemistry; 2002 Jun; 41(23):7391-9. PubMed ID: 12044172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligoproline effects on polyglutamine conformation and aggregation.
    Bhattacharyya A; Thakur AK; Chellgren VM; Thiagarajan G; Williams AD; Chellgren BW; Creamer TP; Wetzel R
    J Mol Biol; 2006 Jan; 355(3):524-35. PubMed ID: 16321399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins.
    Slepko N; Bhattacharyya AM; Jackson GR; Steffan JS; Marsh JL; Thompson LM; Wetzel R
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14367-72. PubMed ID: 16980414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging polyglutamine deposits in brain tissue.
    Osmand AP; Berthelier V; Wetzel R
    Methods Enzymol; 2006; 412():106-22. PubMed ID: 17046655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of the structural organization of polyglutamine aggregates.
    Thakur AK; Wetzel R
    Proc Natl Acad Sci U S A; 2002 Dec; 99(26):17014-9. PubMed ID: 12444250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconsidering the mechanism of polyglutamine peptide aggregation.
    Lee CC; Walters RH; Murphy RM
    Biochemistry; 2007 Nov; 46(44):12810-20. PubMed ID: 17929830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chain length on the aggregation of model polyglutamine peptides: molecular dynamics simulations.
    Marchut AJ; Hall CK
    Proteins; 2007 Jan; 66(1):96-109. PubMed ID: 17068817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unaided trifluoroacetic acid pretreatment solubilizes polyglutamine peptides and retains their biophysical properties of aggregation.
    Burra G; Thakur AK
    Anal Biochem; 2016 Feb; 494():23-30. PubMed ID: 26514067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of polyglutamine disorders: aggregation revisited.
    Michalik A; Van Broeckhoven C
    Hum Mol Genet; 2003 Oct; 12 Spec No 2():R173-86. PubMed ID: 14504263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for modulators of aggregation with a microplate elongation assay.
    Berthelier V; Wetzel R
    Methods Enzymol; 2006; 413():313-25. PubMed ID: 17046403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction.
    Bhattacharyya AM; Thakur AK; Wetzel R
    Proc Natl Acad Sci U S A; 2005 Oct; 102(43):15400-5. PubMed ID: 16230628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solubilization and disaggregation of polyglutamine peptides.
    Chen S; Wetzel R
    Protein Sci; 2001 Apr; 10(4):887-91. PubMed ID: 11274480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathogenic agent in Drosophila models of 'polyglutamine' diseases.
    McLeod CJ; O'Keefe LV; Richards RI
    Hum Mol Genet; 2005 Apr; 14(8):1041-8. PubMed ID: 15757976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface plasmon resonance characterization of specific binding of polyglutamine aggregation inhibitors to the expanded polyglutamine stretch.
    Okamoto Y; Nagai Y; Fujikake N; Akiko Popiel H; Yoshioka T; Toda T; Inui T
    Biochem Biophys Res Commun; 2009 Jan; 378(3):634-9. PubMed ID: 19061859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor.
    Panet-Raymond V; Gottlieb B; Beitel LK; Schipper H; Timiansky M; Pinsky L; Trifiro MA
    Neurotox Res; 2001 Jul; 3(3):259-75. PubMed ID: 15111251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing the conformational ensemble of monomeric polyglutamine.
    Wang X; Vitalis A; Wyczalkowski MA; Pappu RV
    Proteins; 2006 May; 63(2):297-311. PubMed ID: 16299774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic strategies for the polyglutamine diseases].
    Nagai Y; Popiel HA; Fujikake N; Toda T
    Brain Nerve; 2007 Apr; 59(4):393-404. PubMed ID: 17447526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An assay for detecting nanogram levels of proteolytic enzymes.
    Koritsas VM; Atkinson HJ
    Anal Biochem; 1995 May; 227(1):22-6. PubMed ID: 7668384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.